Role of metabolically active hormones in the insulin resistance associated with short-term glucocorticoid treatment

ResearchWorks/Manakin Repository

Search ResearchWorks


Advanced Search

Browse

My Account

Statistics

Related Information

Role of metabolically active hormones in the insulin resistance associated with short-term glucocorticoid treatment

Show simple item record

dc.contributor.author Patel, Jeetesh V. en_US
dc.contributor.author Cummings, David E. en_US
dc.contributor.author Girod, John P. en_US
dc.contributor.author Mascarenhas, Alwin Y. en_US
dc.contributor.author Hughes, Elizabeth A. en_US
dc.contributor.author Gupta, Manjula en_US
dc.contributor.author Lip, Gregory Y. H. en_US
dc.contributor.author Reddy, Sethu en_US
dc.contributor.author Brotman, Daniel J. en_US
dc.date.accessioned 2010-04-21T15:50:02Z
dc.date.available 2010-04-21T15:50:02Z
dc.date.issued 2006 en_US
dc.identifier.citation Patel J, Cummings D, Girod J, et al. Role of metabolically active hormones in the insulin resistance associated with short-term glucocorticoid treatment. Journal of Negative Results in BioMedicine. 2006;5(1):14. en_US
dc.identifier.other 10.1186/1477-5751-5-14 en_US
dc.identifier.uri http://www.jnrbm.com/content/5/1/14 en_US
dc.identifier.uri http://hdl.handle.net/1773/15728
dc.description.abstract Background: The mechanisms by which glucocorticoid therapy promotes obesity and insulin resistance are incompletely characterized. Modulations of the metabolically active hormones, tumour necrosis factor alpha (TNF alpha), ghrelin, leptin and adiponectin are all implicated in the development of these cardiovascular risk factors. Little is known about the effects of short-term glucocorticoid treatment on levels of these hormones. Research methods and procedures: Using a blinded, placebo-controlled approach, we randomised 25 healthy men (mean (SD) age: 24.2 (5.4) years) to 5 days of treatment with either placebo or oral dexamethasone 3 mg twice daily. Fasting plasma TNFa, ghrelin, leptin and adiponectin were measured before and after treatment. Results: Mean changes in all hormones were no different between treatment arms, despite dexamethasone-related increases in body weight, blood pressure, HDL cholesterol and insulin. Changes in calculated indices of insulin sensitivity (HOMA-S, insulin sensitivity index) were strongly related to dexamethasone treatment (p less than 0.001). Discussion: Our data do not support a role for TNF alpha, ghrelin, leptin or adiponectin in the insulin resistance associated with short-term glucocorticoid treatment. en_US
dc.description.sponsorship This work was supported by the Cleveland Clinic Foundation Research Programs Council and the National Institutes of Health [R01 DK61516]. en_US
dc.language.iso en_US en_US
dc.title Role of metabolically active hormones in the insulin resistance associated with short-term glucocorticoid treatment en_US
dc.type Article en_US


Files in this item

Files Size Format View
1477-5751-5-14.pdf 226.4Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record